Intelligent Pain Management System using Synergistic Combinations

Publication ID: 24-11857520_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Intelligent Pain Management System using Synergistic Combinations,” Published Technical Disclosure No. 24-11857520_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857520_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,520.

Summary of the Inventive Concept

A novel system integrating a preservative-free intranasal composition of lidocaine with advanced technologies such as AI, IoT, blockchain, and new materials to provide personalized, optimized, and trackable pain management solutions.

Background and Problem Solved

The original patent disclosed a preservative-free intranasal composition of lidocaine for treating various pain conditions. However, it lacked the capabilities to monitor patient dosage, optimize treatment regimens, and provide personalized care. The new inventive concept addresses these limitations by combining the original composition with cutting-edge technologies to create a more effective and efficient pain management system.

Detailed Description of the Inventive Concept

The system comprises a preservative-free intranasal composition of lidocaine, a mechanical pump metered dose spray device, and a blockchain-based tracking system for monitoring patient dosage and treatment outcomes. Additionally, it incorporates an AI-powered diagnostic tool for identifying optimal dosage and treatment regimens, an IoT-enabled sensor for tracking patient vital signs, and a mobile application for remote monitoring and treatment adjustment. The system also utilizes a novel material composition for enhanced bioavailability and efficacy. Furthermore, it integrates a genetic testing platform for identifying genetic markers associated with pain sensitivity and an AI-powered treatment optimization algorithm for personalized pain management.

Novelty and Inventive Step

The new inventive concept introduces the synergistic combination of a preservative-free intranasal composition of lidocaine with advanced technologies, providing a novel and non-obvious solution for pain management. The integration of blockchain, AI, IoT, and new materials enables real-time monitoring, personalized treatment, and optimized outcomes, which is not disclosed in the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the system may include using different AI algorithms, varying the type of IoT sensors, or incorporating additional technologies such as virtual or augmented reality. The system may also be adapted for use in different pain management applications, such as post-operative care or chronic pain management.

Potential Commercial Applications and Market

The Intelligent Pain Management System has significant commercial potential in the healthcare industry, particularly in the areas of pain management, telemedicine, and personalized medicine. The system's ability to provide optimized and trackable pain management solutions can improve patient outcomes, reduce healthcare costs, and increase market share for pharmaceutical companies and healthcare providers.

CPC Classifications

SectionClassGroup
A A61 A61K31/167
A A61 A61K9/0043
A A61 A61M11/00
A A61 A61M2210/0618

Field of Art

Medical Device Technologies, Pharmaceutical Formulations, Pain Management Systems, with expertise in intranasal drug delivery, medical device design, and digital health technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or related fields, possessing knowledge of drug delivery systems, medical device design, digital health technologies, and interdisciplinary medical innovation strategies

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with established pharmaceutical formulations represents a predictable and incremental advancement in medical treatment. The source patent's preservative-free intranasal lidocaine composition provides a foundational platform for technological enhancement. The PTD's additions of AI, IoT, and tracking technologies represent logical extensions of existing medical technology trends toward personalized, data-driven healthcare solutions.

Obvious Combinations & Variations

Source Patent Element
Preservative-free intranasal lidocaine composition for pain management
PTD Variation
Adding blockchain-based tracking system for monitoring patient dosage and treatment outcomes
Obviousness Reasoning
Tracking patient medication usage is a known technique in digital health, and applying blockchain technology to medical dosage monitoring represents a predictable application of existing technological frameworks
Source Patent Element
Multi-dose nasal spray pump device delivering lidocaine
PTD Variation
Incorporating IoT-enabled sensor for tracking patient vital signs and mobile application for remote monitoring
Obviousness Reasoning
Integrating sensor technologies with medical devices is a well-established trend in personalized medicine, representing an obvious technological progression for improving patient care and treatment monitoring
Source Patent Element
Lidocaine-based pain management method
PTD Variation
Implementing AI-powered diagnostic tool for identifying optimal dosage and treatment regimens
Obviousness Reasoning
Using machine learning and AI for personalized medical treatment optimization is a recognized approach in contemporary medical technology, representing a logical extension of existing diagnostic methodologies
Source Patent Element
Intranasal lidocaine composition for treating neuropathic pain
PTD Variation
Developing novel material composition with nanoparticle-based delivery system for enhanced bioavailability
Obviousness Reasoning
Improving drug delivery through advanced material science is a standard approach in pharmaceutical research, with nanoparticle technologies representing a predictable method for enhancing drug efficacy
Source Patent Element
Pain management method using lidocaine
PTD Variation
Integrating genetic testing platform for identifying pain sensitivity markers
Obviousness Reasoning
Personalized medicine approaches that incorporate genetic testing are increasingly common, representing an obvious technological progression in understanding individual patient responses to treatment
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857520 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable combinations of known medical technologies, digital health innovations, and pharmaceutical delivery methods, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,520
TitleTherapeutic composition of intranasal lidocaine
Assignee(s)Nortic Holdings Inc.